Key Points
- COO Julie Rubinstein sold insider shares: Rubinstein sold 30,941 shares on March 3 at an average $15.67 ($484,845) and another 30,941 on March 5 at $16 ($495,056), reducing her position (her holdings are now 583,911 shares valued at roughly $9.15M).
- Stock and fundamentals snapshot: ADPT fell about 6% to $14.98, after reporting a quarter that beat EPS and revenue estimates with revenue up 51% year-over-year, though the company remains unprofitable (negative margins and ROE); analysts have a "Moderate Buy" consensus with an average target of $18.25.
Adaptive Biotechnologies Corporation (NASDAQ:ADPT - Get Free Report) COO Julie Rubinstein sold 30,941 shares of the stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $15.67, for a total value of $484,845.47. Following the completion of the transaction, the chief operating officer directly owned 583,911 shares in the company, valued at approximately $9,149,885.37. This trade represents a 5.03% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Julie Rubinstein also recently made the following trade(s):
- On Thursday, March 5th, Julie Rubinstein sold 30,941 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $16.00, for a total value of $495,056.00.
Adaptive Biotechnologies Stock Down 6.0%
NASDAQ ADPT traded down $0.95 on Friday, reaching $14.98. The company had a trading volume of 587,082 shares, compared to its average volume of 1,855,177. Adaptive Biotechnologies Corporation has a 52 week low of $6.26 and a 52 week high of $20.76. The stock's 50 day moving average is $16.83 and its 200-day moving average is $15.79. The stock has a market cap of $2.31 billion, a price-to-earnings ratio of -37.45 and a beta of 2.19.
Adaptive Biotechnologies (NASDAQ:ADPT - Get Free Report) last issued its earnings results on Thursday, February 5th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.19) by $0.10. The firm had revenue of $71.68 million for the quarter, compared to analysts' expectations of $59.38 million. Adaptive Biotechnologies had a negative return on equity of 46.68% and a negative net margin of 21.48%.The company's revenue was up 51.0% compared to the same quarter last year. During the same quarter last year, the business earned ($0.23) earnings per share. As a group, analysts forecast that Adaptive Biotechnologies Corporation will post -0.92 EPS for the current year.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently made changes to their positions in the stock. Caitong International Asset Management Co. Ltd bought a new stake in shares of Adaptive Biotechnologies during the fourth quarter worth $28,000. Sound Income Strategies LLC acquired a new position in Adaptive Biotechnologies in the 3rd quarter worth $30,000. EverSource Wealth Advisors LLC boosted its stake in Adaptive Biotechnologies by 197.1% in the 4th quarter. EverSource Wealth Advisors LLC now owns 2,359 shares of the company's stock worth $38,000 after purchasing an additional 1,565 shares during the period. Assetmark Inc. increased its holdings in Adaptive Biotechnologies by 867.9% during the 4th quarter. Assetmark Inc. now owns 3,020 shares of the company's stock worth $49,000 after purchasing an additional 2,708 shares in the last quarter. Finally, T. Rowe Price Investment Management Inc. bought a new position in Adaptive Biotechnologies during the 4th quarter worth about $51,000. Institutional investors and hedge funds own 99.17% of the company's stock.
Wall Street Analysts Forecast Growth
Several brokerages have commented on ADPT. Morgan Stanley began coverage on shares of Adaptive Biotechnologies in a research note on Monday, December 1st. They issued an "equal weight" rating and a $21.00 target price for the company. Piper Sandler set a $21.00 price target on shares of Adaptive Biotechnologies in a report on Friday, February 6th. TD Cowen restated a "buy" rating on shares of Adaptive Biotechnologies in a research report on Friday, February 6th. Wall Street Zen raised Adaptive Biotechnologies from a "hold" rating to a "buy" rating in a research note on Sunday, February 8th. Finally, Guggenheim lifted their target price on Adaptive Biotechnologies from $20.00 to $21.00 and gave the stock a "buy" rating in a report on Monday, January 26th. Seven analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Adaptive Biotechnologies presently has an average rating of "Moderate Buy" and an average target price of $18.25.
Get Our Latest Report on ADPT
About Adaptive Biotechnologies
(
Get Free Report)
Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.
The company's flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
